Recommendations to help ensure a sustainable global market for generics and biosimilars have been set out by the International Generic and Biosimilar Medicines Association in a paper aimed at maintaining “continued patient access worldwide to safe, effective and high-quality medicines.”
In its paper, the IGBA sets out eight specific recommendations.




